Three IL-1 inhibitors (anakinra, rilonacept, and canakinumab), used as a single agent or in combination for treatment of rheumatoid arthritis and IL-1, induced autoimmune disease [98], and can be utilized to reduce IL-1 induced lung inflammation. This evidence concerns the gene IL1B and inflammation.